U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365462) titled 'Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia' on Jan. 22.
Brief Summary: The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Tardive Dyskinesia
Intervention:
DRUG: NBI-1065890
Oral administration
DRUG: Placebo
Oral administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Neurocrine Biosciences
Published by HT Digital Content Services with permission from Health Daily Digest....